Development
Flattening the ‘valley of death’: New tools in the hunt for better preclinical R&D
By Paul Morgan | Feb 23, 2021
Summary
Paul Morgan, Vice President Preclinical Development was recently invited to be part of a panel of senior pharma executives to discuss the key challenges faced by the industry in preclinical R&D. The webinar, hosted by Endpoints News, will be broadcasted on February 23, 2021 at 2-3pm EST.
Webinar
Flattening the ‘valley of death’: New tools in the hunt for better preclinical R&D
Poor rates of attrition from the preclinical R&D stage on is an existential crisis for biopharma players looking to bring better molecules to market. With the rise of artificial intelligence and machine learning, a breakthrough could be on the near horizon. But are those tools all they're cracked up to be? Or does the industry need a fundamental transformation in how it discovers and develops better therapeutics?
Panelists include:
Karen Akinsanya, Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D at Schrodinger
Andrew Hopkins, Founder and CEO of Exscientia
Frank Stegmeier, Chief Scientific Officer at KSQ Therapeutics
Paul Morgan, Vice President Preclinical Development at Sosei Heptares
Moderated by Kyle Blankenship, Managing Editor at Endpoints News
Date: 23 February 2021
Time: 2:00pm to 3:00pm EST